Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, announced two executive appointments as it continues to advance its MXMO macrocycle discovery platform and its oncology pipeline. Marie Evangelista, Ph.D., has been appointed Senior Vice President and Head of Cancer Biology. This appointments align with Circle’s investments in its pipeline of macrocycle therapies, including its lead program, CID-078, currently being evaluated in a Phase 1 clinical trial in solid tumors.
Dr. Evangelista has more than 18 years of experience in translational oncology and small molecule drug discovery, having successfully led programs from early discovery to clinical development. Prior to joining Circle, she spent 15 years at Genentech where her leadership was instrumental in advancing Genentech’s KRAS-targeting programs. Following Genentech, Dr. Evangelista held senior leadership roles at Frontier Medicines and most recently at Recursion. Dr. Evangelista holds a Ph.D. in cell and molecular biology from Queen’s University in Ontario, Canada.
Also Read: Trailhead Biosystems Names Joshua Snow as CCO
“I’m excited to join Circle at this important juncture, where its innovative macrocycle platform is translating into clinical progress,” said Dr. Evangelista. “I look forward to contributing to the development of transformative therapies for patients.”
About Circle Pharma, Inc.
South San Francisco-based Circle Pharma is advancing the discovery and development of intrinsically cell-permeable macrocycles that can be delivered by multiple routes, including oral administration. Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry to develop a new generation of macrocycle therapies for challenging targets to address unmet clinical needs. Circle Pharma is focusing its development efforts on cyclins, which are master regulators of the machinery that controls the progression of cells through the cell cycle and are key drivers in many cancers
Source: Businesswire